Most importantly, the GPR68-targeting small molecule inhibitor OGM-8345 exerts robust protection against acidosis-induced endothelial dysfunction, suggesting that it could be considered as a potential therapeutic drug candidate to restore endothelial function and treat associated lung injuries. This evidence concerns the gene GPR68 and endothelial dysfunction.